{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:32Z","timestamp":1789469132381,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ24H290001"],"award-info":[{"award-number":["LQ24H290001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Major and Difficult Diseases (Lymphoma) Clinical Collaboration Project of Traditional Chinese and Western Medicine","award":["ZDYN-2024-A-024"],"award-info":[{"award-number":["ZDYN-2024-A-024"]}]},{"name":"Special Project for the Modernization of Traditional Chinese Medicine in Zhejiang Province","award":["2020ZX007"],"award-info":[{"award-number":["2020ZX007"]}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["LY19H270004"],"award-info":[{"award-number":["LY19H270004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07150-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:36:59Z","timestamp":1784090219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful eradication of de novo HLA antibodies with daratumumab in immune-mediated cytopenias after allogeneic stem cell transplantation: a case report"],"prefix":"10.1007","volume":"105","author":[{"given":"Xianfu","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangping","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"7150_CR1","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2024015405","volume":"9","author":"NS Bhatt","year":"2025","unstructured":"Bhatt NS, Borogovac A, Efebera YA, DeSalvo A, Devine SM, Foley A, Greco-Stewart V, Hamilton BK, Heuer M, Molfenter T, Plastaras JP, Ragon BK, Wall SA, Broglie L, Juckett MB, Khera N, Horowitz MM, DeZern AE (2025) Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice. Blood Adv 9:4448\u20134457. https:\/\/doi.org\/10.1182\/bloodadvances.2024015405","journal-title":"Blood Adv"},{"key":"7150_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41409-020-01169-7","volume":"56","author":"ZL Xu","year":"2021","unstructured":"Xu ZL, Huang XJ (2021) Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transplant 56:779\u2013785. https:\/\/doi.org\/10.1038\/s41409-020-01169-7","journal-title":"Bone Marrow Transplant"},{"key":"7150_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41409-018-0410-3","volume":"54","author":"ZL Xu","year":"2019","unstructured":"Xu ZL, Zhou M, Jia JS, Mo WJ, Zhang XH, Zhang YP, Wang Y, Li YM, Huang XJ, Wang SQ, Xu LP (2019) Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplant 54:1319\u20131326. https:\/\/doi.org\/10.1038\/s41409-018-0410-3","journal-title":"Bone Marrow Transplant"},{"key":"7150_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/bmt.2016.223","volume":"52","author":"YB Choi","year":"2017","unstructured":"Choi YB, Yi ES, Lee JW, Sung KW, Koo HH, Yoo KH (2017) Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor. Bone Marrow Transplant 52:47\u201352. https:\/\/doi.org\/10.1038\/bmt.2016.223","journal-title":"Bone Marrow Transplant"},{"key":"7150_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2450\/BloodTransfus.790","volume":"23","author":"U La Rocca","year":"2025","unstructured":"La Rocca U, Ricci R, Piciocchi A, Barberi W, Oldani E, Dominietto A, Cerretti R, Picardi A, Bonifazi F, Saccardi R, Faraci M, Grillo G, Farina L, Bruno B, Grassi A, Proia A, Tagliaferri E, De Simone G, Malagola M, Cerno M, Cesaro S, Bernasconi P, Prezioso L, Carluccio P, Mordini N, Pelosini M, Olivieri A, Chiusolo P, Santarone S, Cimminiello M, Crocchiolo R, Papola F, Rombola G, Sacchi N, Miotti V, Mele L, Mazzi B, Ciceri F, Martino M, Iori AP (2025) Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT: anti-HLA and DSA management in Italian Transplant Programs. Blood Transfus 23:176\u2013185. https:\/\/doi.org\/10.2450\/BloodTransfus.790","journal-title":"Blood Transfus"},{"key":"7150_CR6","doi-asserted-by":"publisher","first-page":"687 e1","DOI":"10.1016\/j.jtct.2021.04.030","volume":"27","author":"Y Xie","year":"2021","unstructured":"Xie Y, Parekh J, Tang Z, Wu D, Wu X (2021) Donor-specific antibodies and primary graft failure in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther 27:687 e1\u2013687 e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.030","journal-title":"Transplant Cell Ther"},{"key":"7150_CR7","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.retram.2024.103464","volume":"72","author":"A Milano","year":"2024","unstructured":"Milano A, Lando G, Di Maggio G, Cornacchini G, Grillo G, Cairoli R, Rossini S, Crocchiolo R (2024) Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation. Curr Res Transl Med 72:103464. https:\/\/doi.org\/10.1016\/j.retram.2024.103464","journal-title":"Curr Res Transl Med"},{"key":"7150_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/tan.70392","volume":"106","author":"B Valatkaite-Rakstiene","year":"2025","unstructured":"Valatkaite-Rakstiene B, Kviliute R, Jakubauskas A (2025) De novo HLA antibodies are associated with an increased risk of severe acute graft-versus-host disease following unrelated donor haematopoietic stem cell transplantation. HLA 106:e70392. https:\/\/doi.org\/10.1111\/tan.70392","journal-title":"HLA"},{"key":"7150_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1047200","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Ji K, Chen L, Li Y, Zhu W, Yuan X, Bao X, Wu X, He J (2022) Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies. Front Immunol 13:1047200. https:\/\/doi.org\/10.3389\/fimmu.2022.1047200","journal-title":"Front Immunol"},{"key":"7150_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00431-023-04912-6","volume":"182","author":"M Spadea","year":"2023","unstructured":"Spadea M, Saglio F, Ceolin V, Barone M, Zucchetti G, Quarello P, Fagioli F (2023) Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment. Eur J Pediatr 182:2471\u20132483. https:\/\/doi.org\/10.1007\/s00431-023-04912-6","journal-title":"Eur J Pediatr"},{"key":"7150_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/s41409-020-01179-5","volume":"56","author":"AO Gupta","year":"2021","unstructured":"Gupta AO, Jan Boelens J, Ebens CL, Kurtzberg J, Lund TC, Smith AR, Wagner JE, Wynn R, Blazar BR, Orchard PJ (2021) Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplant 56:1238\u20131247. https:\/\/doi.org\/10.1038\/s41409-020-01179-5","journal-title":"Bone Marrow Transplant"},{"key":"7150_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41409-022-01578-w","volume":"57","author":"B File","year":"2022","unstructured":"File B, Huang Y, Peedin A, Gergis U (2022) The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies. Bone Marrow Transplant 57:526\u2013531. https:\/\/doi.org\/10.1038\/s41409-022-01578-w","journal-title":"Bone Marrow Transplant"},{"key":"7150_CR13","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1182\/bloodadvances.2021004862","volume":"5","author":"SO Ciurea","year":"2021","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao K (2021) Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 5:4031\u20134043. https:\/\/doi.org\/10.1182\/bloodadvances.2021004862","journal-title":"Blood Adv"},{"key":"7150_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/09537104.2019.1624706","volume":"30","author":"Y Li","year":"2019","unstructured":"Li Y, Shi Y, He Z, Chen Q, Liu Z, Yu L, Wang C (2019) The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis. Platelets 30:690\u2013697. https:\/\/doi.org\/10.1080\/09537104.2019.1624706","journal-title":"Platelets"},{"key":"7150_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.17648","volume":"196","author":"M Gabelli","year":"2021","unstructured":"Gabelli M, Ademokun C, Cooper N, Amrolia PI (2021) Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol 196:45\u201362. https:\/\/doi.org\/10.1111\/bjh.17648","journal-title":"Br J Haematol"},{"key":"7150_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224203","author":"P Fiorina","year":"2019","unstructured":"Fiorina P, Tomita Y, Iwadoh K, Ogawa Y, Miki K, Kato Y, Kai K, Sannomiya A, Koyama I, Kitajima K, Nakajima I, Fuchinoue S (2019) Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0224203","journal-title":"PLoS One"},{"key":"7150_CR17","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C Muller","year":"2012","unstructured":"Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276\u201384. https:\/\/doi.org\/10.1182\/blood-2011-09-380949","journal-title":"Blood"},{"key":"7150_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.healun.2015.05.001","volume":"34","author":"CA Irving","year":"2015","unstructured":"Irving CA, Carter V, Gennery AR, Parry G, Griselli M, Hasan A, Kirk CR (2015) Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant 34:1310\u20137. https:\/\/doi.org\/10.1016\/j.healun.2015.05.001","journal-title":"J Heart Lung Transplant"},{"key":"7150_CR19","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/ajt.12750","volume":"14","author":"S Mittal","year":"2014","unstructured":"Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV (2014) De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant 14:1664\u201371. https:\/\/doi.org\/10.1111\/ajt.12750","journal-title":"Am J Transplant"},{"key":"7150_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133731","author":"G Baudry","year":"2022","unstructured":"Baudry G, Pozzi M, Aubry M, Hugon-Vallet E, Mocan R, Chalabreysse L, Portran P, Obadia JF, Thaunat O, Girerd N, Dubois V, Sebbag L (2022) De novo complement-binding anti-HLA antibodies in heart transplanted patients is associated with severe cardiac allograft vasculopathy and poor long-term survival. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11133731","journal-title":"J Clin Med"},{"key":"7150_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MOH.0000000000000902","volume":"33","author":"L Pan","year":"2026","unstructured":"Pan L, Zhu J (2026) Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives. Curr Opin Hematol 33:34\u201342. https:\/\/doi.org\/10.1097\/MOH.0000000000000902","journal-title":"Curr Opin Hematol"},{"key":"7150_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tmrv.2020.09.010","volume":"34","author":"A Saris","year":"2020","unstructured":"Saris A, Pavenski K (2020) Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev 34:250\u2013257. https:\/\/doi.org\/10.1016\/j.tmrv.2020.09.010","journal-title":"Transfus Med Rev"},{"key":"7150_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.imlet.2014.11.013","volume":"163","author":"A Finkielsztein","year":"2015","unstructured":"Finkielsztein A, Schlinker AC, Zhang L, Miller WM, Datta SK (2015) Human megakaryocyte progenitors derived from hematopoietic stem cells of normal individuals are MHC class II-expressing professional APC that enhance Th17 and Th1\/Th17 responses. Immunol Lett 163:84\u201395. https:\/\/doi.org\/10.1016\/j.imlet.2014.11.013","journal-title":"Immunol Lett"},{"key":"7150_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2141.1992.tb02991.x","volume":"81","author":"LK Boshkov","year":"1992","unstructured":"Boshkov LK, Kelton JG, Halloran PF (1992) HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura. Br J Haematol 81:552\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.1992.tb02991.x","journal-title":"Br J Haematol"},{"key":"7150_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1625365","author":"X-y Jing","year":"2025","unstructured":"Jing X-y, Li D-j, Su S-n, Dai Q-k, Sun S-w, Huang L, Ai Y, Gao J, Zhu Y-P, Ni J-q, Lu X-x (2025) Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1625365","journal-title":"Front Immunol"},{"key":"7150_CR26","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.16171","volume":"187","author":"R Blennerhassett","year":"2019","unstructured":"Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A (2019) Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol 187:e48\u2013e51. https:\/\/doi.org\/10.1111\/bjh.16171","journal-title":"Br J Haematol"},{"key":"7150_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28010","volume":"67","author":"E Even-Or","year":"2020","unstructured":"Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, Zaidman I, Stepensky P (2020) Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer 67:e28010. https:\/\/doi.org\/10.1002\/pbc.28010","journal-title":"Pediatr Blood Cancer"},{"key":"7150_CR28","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","volume":"379","author":"CI Chapuy","year":"2018","unstructured":"Chapuy CI, Kaufman RM, Alyea EP, Connors JM (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 379:1846\u20131850. https:\/\/doi.org\/10.1056\/NEJMoa1807438","journal-title":"N Engl J Med"},{"key":"7150_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/trf.16281","volume":"61","author":"B Yates","year":"2021","unstructured":"Yates B, Molloy E, Dulau-Florea A, Braylan R, Hogan L, Hickstein DD, Freeman AF, Kalsi SS, Shah NN (2021) Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation. Transfusion 61:1041\u20131046. https:\/\/doi.org\/10.1111\/trf.16281","journal-title":"Transfusion"},{"key":"7150_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2023.102724","volume":"99","author":"I Vernava","year":"2023","unstructured":"Vernava I, Schmitt CA (2023) Daratumumab as a novel treatment option in refractory ITP. Blood Cells Mol Dis 99:102724. https:\/\/doi.org\/10.1016\/j.bcmd.2023.102724","journal-title":"Blood Cells Mol Dis"},{"key":"7150_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2025.102323","volume":"93","author":"V Chiavetta","year":"2025","unstructured":"Chiavetta V, Soldarini M, Cafro AM, Bertazzoni P, Lando G, Di Maggio G, Sole T, Pioltelli ML, Cuppari I, Corso A, Sulejmani A, Cairoli R, Volpato E, Crocchiolo R (2025) Targeting CD38 to reduce anti-HLA antibody levels: a new and effective option to be integrated into desensitization protocols? Transpl Immunol 93:102323. https:\/\/doi.org\/10.1016\/j.trim.2025.102323","journal-title":"Transpl Immunol"},{"key":"7150_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.htct.2021.11.019","volume":"45","author":"U Ibrahim","year":"2023","unstructured":"Ibrahim U, Keyzner A (2023) Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation. Hematol Transfus Cell Ther 45:510\u2013512. https:\/\/doi.org\/10.1016\/j.htct.2021.11.019","journal-title":"Hematol Transfus Cell Ther"},{"key":"7150_CR33","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.ekir.2024.08.020","volume":"9","author":"C Pilon","year":"2024","unstructured":"Pilon C, Joher N, Usureau C, Boutin E, Boueilh A, Taupin JL, Thiolat A, Cohen JL, Kheav VD, Canoui-Poitrine F, Carmagnat M, Grimbert P, Matignon M (2024) Open-label phase 1\/2 study of Daratumumab-based desensitization before kidney transplantation. Kidney Int Rep 9:3250\u20133264. https:\/\/doi.org\/10.1016\/j.ekir.2024.08.020","journal-title":"Kidney Int Rep"},{"key":"7150_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12288-023-01712-8","volume":"40","author":"P Mehta","year":"2023","unstructured":"Mehta P, Raut S, Rastogi N, Kumar M, Dua V, Bhargava R (2023) Daratumumab for de-sensitization of donor specific antibodies: is it a quicker and easier way? Indian J Hematol Blood Transfus 40:508\u2013510. https:\/\/doi.org\/10.1007\/s12288-023-01712-8","journal-title":"Indian J Hematol Blood Transfus"},{"key":"7150_CR35","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/j.clml.2020.04.004","volume":"20","author":"S Al Hadidi","year":"2020","unstructured":"Al Hadidi S, Miller-Chism CN, Kamble R, Mims M (2020) Safety analysis of five randomized controlled studies of Daratumumab in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 20:e579\u2013e589. https:\/\/doi.org\/10.1016\/j.clml.2020.04.004","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07150-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:45Z","timestamp":1789465365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7150"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07150-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University. Written informed consent was obtained from the patients for the publication of any potentially identifiable images or data included in this article.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"375"}}